Gapping up
In reaction to strong earnings/guidance:
- BOOM +11.5%, RMD +10.4%, ANIK +8%, SPSC +7.7%, DLX +7.1%, WPP +6.9%, ALGT +6%, CHTR +5.7%, MHK +5.4%, JNPR +5.1%, CVA +4%, INTC +3.7%, AUY +3.3%, SWN +3%, VRTS +3%, PBR +3%, GBX +2.9%, OSIS +2.5%, BCS +1.5%, ALK +1.3%, DECK +1.3%, LEA +1.2%, TILE +1.1%, CCMP +1%, VZ +1%, COG +0.9%, FET +0.8%, ALV +0.8%, FII +0.7%, GLPG +0.7%, YNDX +0.7%, VTR +0.7%
Other news:
- NCNA +25.3% (receives FDA clearance for Investigational New Drug Application for Phase III study (NuTide:121) of Acelarin in combination with cisplatin for patients with biliary tract cancer)
- ACRS +15.5% (announces "positive" results from second Phase 3 clinical trial of A-101 45%; study met primary and all secondary endpoints)
- SENS +9.8% (Senseonics announces that Humana is now providing coverage for the Eversense CGM System and insertion procedure)
- KREF +6.2% (to join S&P SmallCap 600)
- IPOA +2.8% (as disclosed earlier today, the co expects to close the Business Combination with Virgin Galactic on October 25)
- TXMD +1.4% (prices offering of 26 mln shares of common stock at $2.75 per share)
- BYND +1.2% (appoints Stuart Kronauge as Chief Marketing Officer)
- ATVI +1.2% (following today's unusual options activity and Fast Money mention)
- KMX +0.9% (promotes Enrique Mayor-Mora to CFO)
Analyst comments:
- MNKD +2.4% (initiated with Overweight at Cantor Fitzgerald; tgt $3)
- CDAY +2% (upgraded to Buy from Neutral at Citigroup)
- FITB +1.4% (upgraded to Buy from Neutral at UBS)
- PFNX +1.2% (initiated with Overweight at Cantor Fitzgerald; tgt $20)
- SMG +0.8% (upgraded to Buy from Neutral at BofA/Merrill)